WILLIAM K PLUNKETT JR to Drug Synergism
This is a "connection" page, showing publications WILLIAM K PLUNKETT JR has written about Drug Synergism.
Connection Strength
0.557
-
Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease. Clin Cancer Res. 2011 Jul 15; 17(14):4731-41.
Score: 0.074
-
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood. 2011 Jan 06; 117(1):156-64.
Score: 0.071
-
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006 Nov 15; 66(22):10959-66.
Score: 0.054
-
Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood. 2006 Dec 15; 108(13):4187-93.
Score: 0.053
-
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia. 2006 Apr; 20(4):610-9.
Score: 0.052
-
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res. 2001 Feb 01; 61(3):1065-72.
Score: 0.036
-
Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res. 2000 Mar; 6(3):773-81.
Score: 0.034
-
Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995 Aug; 22(4 Suppl 11):3-10.
Score: 0.025
-
Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol. 1995 May; 47(5):1072-9.
Score: 0.024
-
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol. 1994; 34(1):30-6.
Score: 0.022
-
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993 Jan; 11(1):116-24.
Score: 0.021
-
Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992 Feb 15; 52(4):897-903.
Score: 0.019
-
Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother Pharmacol. 1992; 31(1):11-7.
Score: 0.019
-
Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol. 1988; 22(3):205-10.
Score: 0.015
-
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood. 2006 Aug 01; 108(3):993-1000.
Score: 0.013
-
Inhibition of adenosine deaminase to increase the antitumor activity of adenine nucleoside analogues. Ann N Y Acad Sci. 1985; 451:150-9.
Score: 0.012
-
Increased toxicity of 9-beta-D-arabinofuranosyladenine in the presence of an inhibitor of adenosine deaminase. Ann N Y Acad Sci. 1977 Mar 04; 284:91-102.
Score: 0.007
-
Two approaches that increase the activity of analogs of adenine nucleosides in animal cells. Cancer Res. 1975 Jun; 35(6):1547-54.
Score: 0.006